Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Iyad Khourdaji, MD

Advertisement

Articles by Iyad Khourdaji, MD

Streamlined management of Peyronie’s disease

ByIyad Khourdaji, MD,Ryan P. Smith, MD,Raymond A. Costabile, MD
February 1st 2018

In this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.

Advertisement

Latest Updated Articles

  • Streamlined management of Peyronie’s disease
    Streamlined management of Peyronie’s disease

    February 1st 2018



Advertisement
Advertisement

Trending on Urology Times

1

John Sfakianos, MD, on integrating ctDNA into bladder cancer trials

2

FDA updates in urology: September 2026

3

SBRT, prostatectomy show comparable long-term disease control in PACE-A trial

4

Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR

5

Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us